Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. (ZTS) drives innovation in animal health as the global leader in veterinary pharmaceuticals and diagnostics. This news hub provides investors and industry professionals with essential updates on developments impacting companion animal care and livestock health systems.
Access curated press releases and analysis covering product approvals, research breakthroughs, and financial performance. Our repository includes updates on vaccine innovations, parasiticides, diagnostic tools, and strategic partnerships across 100+ markets. Monitor earnings announcements, manufacturing expansions, and regulatory milestones that shape this $80B sector.
Bookmark this page for streamlined tracking of Zoetis' operational progress in developing solutions for pets and farm animals. Return regularly to stay informed about initiatives affecting animal welfare standards and agricultural productivity worldwide.
The Zoetis Foundation announced a commitment of $4.9 million to support 20 initiatives across Africa, Brazil, China, Ukraine, and the U.S. The funds will enhance veterinary scholarships, diversity programming, and mental wellness, while also aiding livestock farmers and relief efforts in Ukraine. An initial donation of $150,000 has been made to the Red Cross, with a matching commitment of up to $150,000 for colleague donations. The Foundation aims to improve livelihoods, education, and mental health support for veterinarians and farmers, backed by an overall $35 million commitment through 2025.
Zoetis Inc (NYSE:ZTS) will host a webcast and conference call on May 5, 2022, at 8:30 a.m. (ET) to discuss its first quarter 2022 financial results. CEO Kristin Peck and CFO Wetteny Joseph will lead the call. Investors can access the live webcast via the Zoetis investor website. Zoetis, the world's leading animal health company, generated $7.8 billion in revenue in 2021 and employs approximately 12,100 people globally. More details and a replay of the call will be available on the website.
Zoetis (NYSE:ZTS) will attend the Barclays Global Healthcare Conference on March 17, 2022, where Wetteny Joseph, Executive Vice President and CFO, will present at 9:30 a.m. ET. Interested investors can access a live audio webcast of the presentation at http://investor.zoetis.com/events-presentations. A replay will be available on the Zoetis website afterward. Zoetis, a leading animal health company, generated $7.8 billion in revenue in 2021 and operates in over 100 countries.
Zoetis (NYSE:ZTS) will participate in the Bank of America Securities 2022 Animal Health Summit on February 24, 2022. Wetteny Joseph, CFO, will present at 2:30 p.m. ET, answering questions from analysts. The event will be accessible via a live audio webcast, available at investor.zoetis.com/events-presentations, with a replay provided afterwards. Zoetis is a leader in animal health, generating $7.8 billion in revenue in 2021, with innovations in medicines and diagnostics serving over 100 countries.
For Q4 2021, Zoetis reported $2.0 billion in revenue, marking a 9% increase year-over-year. Net income rose to $414 million or $0.87 per diluted share. For the full year, revenue reached $7.8 billion, a 16% growth, with net income at $2.0 billion or $4.27 per share. Zoetis anticipates 2022 revenues between $8.325 billion to $8.475 billion, projecting operational growth of 9% to 11%. The company achieved significant sales growth in its companion animal products, despite declines in livestock products due to competition and pricing pressures.
Zoetis Inc. (NYSE:ZTS) has announced a quarterly dividend of $0.325 per share, set for payment on June 1, 2022. This dividend will be distributed to all stockholders on record as of April 21, 2022. With a strong revenue of $6.7 billion in 2020, Zoetis stands as a leader in animal health, providing innovative solutions worldwide. This financial return reflects Zoetis's commitment to its shareholders and reinforces its robust market position.
Zoetis Inc. (NYSE:ZTS) announced FDA approval for Solensia™, the first injectable monoclonal antibody treatment for feline osteoarthritis (OA) pain. This once-monthly injection targets Nerve Growth Factor (NGF), effectively controlling OA pain and enhancing feline mobility and well-being. Studies show that 77% of cat owners observed improved pain signs in their cats after treatment. With nearly 40% of cats affected by OA, Solensia addresses a crucial need in veterinary care. It is anticipated to be available to veterinarians in the second half of 2022.
Zoetis (NYSE:ZTS) announced its commitment to achieving carbon neutrality in its operations by 2030. The initiative includes transitioning to 100% renewable energy, highlighted by a virtual power purchase agreement with Vesper Energy to supply 33% of its North American operational energy needs. Currently, 9 out of 28 manufacturing sites and several offices are already using 100% renewable electricity. Zoetis aims to enhance energy efficiency and transparency regarding emissions, reinforcing its sustainability leadership in animal health.
Zoetis (NYSE:ZTS) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022. CEO Kristin Peck is scheduled to present at 1:30 p.m. ET and will answer questions from analysts. Interested investors can access a live audio webcast of the presentation at http://investor.zoetis.com/events-presentations, with a replay available afterward. Zoetis is a leading animal health company with a revenue of $6.7 billion in 2020, supporting animal care globally.
FAQ
What is the current stock price of Zoetis (ZTS)?
What is the market cap of Zoetis (ZTS)?
